- W. L. Gore & Associates, Inc. GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis (REVISE). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine; 2014. https://clinicaltrials.gov/ct2/show/NCT00737672 Published August 15, 2008. Updated October 14, 2014. September 11, 2019. NLM Identifier: NCT00737672.
- 2. Flair® Endovascular Stent Graft [Instructions for Use]. Tempe, AZ: C. R. Bard, Inc; 2014. B05659 Rev.3/08-14.
- 3. Covera[®] Vascular Covered Stent [Instructions for Use]. Tempe, AZ: C. R. Bard, Inc; 2018. B05872 Rev.4/08-18.
- 4. Haskal ZJ, Trerotola S, Dolmatch B, et al. Stent graft versus balloon angioplasty for failing dialysis-access grafts. New England Journal of Medicine 2010;362(6):494-503.
- Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. *Journal of Vascular Surgery* 2016;64(5):1400–1410.e1. https://www.sciencedirect.com/science/article/pii S0741521416301756
- 6. Vesely T, Rodriguez A. Summary of the Gore REVISE Clinical Study. Endovascular Today 2014;13(6)Supplement:22-26.
- Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators. Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial. *Journal of Vascular & Interventional Radiology* 2018;30(2):203-211.e4.

Consult Instructions for Use eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. R_{conv}

Products listed may not be available in all markets.

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.

GORE, *Together, improving life,* PROPATEN, VIABAHN and designs are trademarks of W. L. Gore & Associates. © 2024 W. L. Gore & Associates GmbH 24PL2147-EN01 NOVEMBER 2024

W. L. Gore & Associates, Inc. goremedical.com

 Asia Pacific +65 6733 2882
 Australia/New Zealand 1800 680 424
 Europe 00800 6334 4673

 United States Flagstaff, AZ 86004
 800 437 8181
 928 779 2771



GORE **REVISE** CLINICAL STUDY

GORE[®] VIABAHN[®] Endoprosthesis with PROPATEN Bioactive Surface*

Gore clinical study receives **JVIR editor's award** for outstanding clinical research paper for 2019 from *Journal of Vascular and Interventional Radiology*



*As used by Gore, PROPATEN Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface.

Gore REVISE Clinical Study

The REVISE Study is a multicenter, randomized, controlled trial that demonstrated the safety and effectiveness of the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous access of prosthetic grafts at the venous anastomosis in thrombotic or stenotic (dysfunctional) vascular access for hemodialysis. The REVISE Study randomized against percutaneous transluminal angioplasty (PTA) and follow-ups tracked the natural course of vascular access and reinterventions as the subject underwent regular hemodialysis.

The REVISE Study is the only study to include an endoprosthesis across the elbow and the only randomized control trial to include thrombosed grafts.¹⁻⁴



Results and key takeaways

Target lesion primary patency in the VIABAHN[®] Device group was significantly higher than the PTA group (P = .008)⁵

This was true at every time point through the 24-month analysis period. At 6 months, target lesion primary patency was 52.9% in the VIABAHN[®] Device group and 35.5% in the PTA group.^{1,5}

6-month target lesion primary patency



Circuit primary patency of the VIABAHN® Device showed a nearly 50% relative increase compared to PTA⁵

This was true at every time point from the 6-month to the 24-month analysis period.⁵

Six-month circuit primary patency



VIABAHN[®] Device

The VIABAHN[®] Device provided consistent patency independent of number of times a lesion had previously been treated⁵

The REVISE Study shows that the patency of the VIABAHN® Device will not decrease due to multiple previous interventions while the PTA treated graft will decrease.⁵

6-month target lesion patency with intervention history



Datency (%)

PTA Group n = 138 Secondary patency across the elbow at 2 years is 83% with zero reported fractures.⁶ The VIABAHN[®] Device is shown to re-establish flow to stenosed (dysfunctional) grafts in points of flexion.^{5,6}

The VIABAHN[®] Device demonstrated a reduction in the number of repeat interventions per patient with thrombosed grafts as compared to PTA, by reducing the mean number of future interventions over 2 years by 40% (3.7 for the VIABAHN[®] Device versus 6.2 for PTA),⁷ *Figure 1*.

The VIABAHN[®] Device has strong clinical and health economic data to support the treatment of a thrombosed prosthetic graft. The reduction of interventions over a two year period by 40% reduces cost by \sim \$12K per patient,⁷ Figures 2–3.



Figure 1. All reintervention types: Thrombosed circuits



Figure 3. Reintervention costs: Thrombosed circuits

